Patients with advanced cancer and few treatment options are interested in tumour molecular profiling but less willing to pay for it, according to new Australian research. In a sub-study of the Molecular Screening and Therapeutics (MoST) Program, 777 patients were presented with scenarios around the likelihood of molecular profiling returning an actionable variant and the ...
Patients want molecular profiling of tumours: but who will pay for it?
By Mardi Chapman
26 May 2020